REPLY:We thank Drs. Bhargava and Delpassand for bringing our attention to their recent work in radiopeptide therapy of neuroendocrine tumors with 177Lu and 111In. We agree that the approach is very promising and needs to be brought into clinical practice in the United States, as it is now being widely used in Europe.
Footnotes
Published online Mar. 19, 2012.
- © 2012 by the Society of Nuclear Medicine, Inc.